Sensitivity to the pan-KRAS “OFF” inhibitor BI-2493 was assessed across a large panel of cancer cell lines, using a high-throughput PRISM platform–based cellular screen, which allows pooled screening of mixtures of 900+ cancer cell lines derived from 140 tumor types (Supplementary Table S1; ref. 30). Here, KRAS is linked to neoplasm.